A226330 Stock Overview
Operates as a genomic big data and artificial intelligence drug discovery company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SyntekaBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,420.00 |
| 52 Week High | ₩14,880.00 |
| 52 Week Low | ₩4,195.00 |
| Beta | 0.62 |
| 11 Month Change | 44.59% |
| 3 Month Change | -1.08% |
| 1 Year Change | -45.73% |
| 33 Year Change | -45.36% |
| 5 Year Change | n/a |
| Change since IPO | -61.56% |
Recent News & Updates
Shareholder Returns
| A226330 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | 13.0% | 12.7% | 2.9% |
| 1Y | -45.7% | -40.1% | -2.8% |
Return vs Industry: A226330 underperformed the KR Healthcare Services industry which returned -40.1% over the past year.
Return vs Market: A226330 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A226330 volatility | |
|---|---|
| A226330 Average Weekly Movement | 10.6% |
| Healthcare Services Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A226330's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A226330's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 63 | n/a | www.syntekabio.com |
SyntekaBio, Inc. operates as a genomic big data and artificial intelligence drug discovery company. It creates new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology, such as biomarkers for individual cancer drug screening and disease susceptibility by immunotyping, pharmacogenomic typing, and predicting multi-omics information-based drug adverse effects, etc. The company also developing new antigen prediction technology that can be used together with therapeutic vaccines and cell therapy products, and prediction of antibody therapeutics. SyntekaBio, Inc. was founded in 2009 and is headquartered in Daejeon, South Korea.
SyntekaBio, Inc. Fundamentals Summary
| A226330 fundamental statistics | |
|---|---|
| Market cap | ₩97.96b |
| Earnings (TTM) | -₩7.42b |
| Revenue (TTM) | ₩124.38m |
787.6x
P/S Ratio-13.2x
P/E RatioIs A226330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A226330 income statement (TTM) | |
|---|---|
| Revenue | ₩124.38m |
| Cost of Revenue | ₩2.57m |
| Gross Profit | ₩121.82m |
| Other Expenses | ₩7.54b |
| Earnings | -₩7.42b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -486.36 |
| Gross Margin | 97.94% |
| Net Profit Margin | -5,966.30% |
| Debt/Equity Ratio | 21.8% |
How did A226330 perform over the long term?
See historical performance and comparison